Pharmacokinetic parameter driven outcomes model predicts a reduction in bleeding events associated with BAY 81–8973 versus antihemophilic factor (recombinant) plasma/albumin-free method in a Chinese healthcare setting

BACKGROUND: Long-term prophylactic therapy is considered the standard of care for hemophilia A patients. This study models the long-term clinical and cost outcomes of two factor VIII (FVIII) products using a pharmacokinetic (PK) simulation model in a Chinese population. METHODS: Head-to-head PK prof...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Rong, Gultyaev, Dmitry, Lister, Johanna, Han, Rong, Hu, Nan, Malacan, Jean, Solms, Alexander, Vashi, Parth, O’Hara, Jamie, Hu, Shanlian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9356410/
https://www.ncbi.nlm.nih.gov/pubmed/35931967
http://dx.doi.org/10.1186/s12874-022-01659-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9356410/
https://www.ncbi.nlm.nih.gov/pubmed/35931967
http://dx.doi.org/10.1186/s12874-022-01659-w

Ejemplares similares